Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

NCT01594281 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Proliferative Diabetic Retinopathy (PDR)

Interventions

DRUG: Ranibizumab 0.5 mg
PROCEDURE: Panretinal laser photocoagulation

Sponsor

Novartis Pharmaceuticals